Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CpG-ODN in Malignant Glioblastoma
NCT00190424Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2005
- Primary completion
- Oct 2008
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CpG-28 oligodeoxynucleotide in glioblastoma (GBM) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Overall Survival at 2 years. Started Sep 2005; status: completed.
02
Drugs
CpG-28 oligodeoxynucleotide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00190424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00190424.